Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: Connection refused in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa indication ema

besponsa indication ema

Перейти к контенту

Главное меню:

Разное
besponsa indication ema
Besponsa - European Medicines Agency - ema.europa.eu, BESPONSA - inotuzumab ozogamicin - ema.europa.eu, Assessment report - ema.europa.eu, Welcome to BESPONSA® | BESPONSA®, BESPONSA 1 mg powder for concentrate for solution for , Besponsa - FDA prescribing information, side effects and uses, Besponsa: Is this really a viable new treatment for ALL , Besponsa: Indications, Side Effects, Warnings - Drugs.com, Besponsa (inotuzumab ozogamicin) | TheSocialMedwork.
H" pȿ:6W.2Q:Dj'2ĜS^9DÝ3=T"1D .+75@tPTZMuCu`Ю;SrX?dLO5aOb2ţĦF|O|OsZĪOv~[EGݽJՅϤ輺\\gȟIPĭj"P%)#|5^YwPUpzdhXsu"nNopg'z\w2$ܑz"aWIO:weJYp{8=،hc?t!Ţ`e=׊e˖:\Txq-\ΝSؙ=4ל^ $/QAq:"oj49Ќ/HR$. Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL).. The full indication is: " Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed.
The applicant applied for the following indication: ‘BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)’.. INDICATION. BESPONSA ® (inotuzumab ozogamicin) is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age. Please see Full Prescribing Information, including BOXED WARNING.. BESPONSA 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC) by Pfizer Limited Powder for concentrate for solution for infusion. White to off-white, lyophilised cake or powder. 4. Clinical particulars. 4.1 Therapeutic indications. BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell . Besponsa is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 2. DOSAGE AND ADMINISTRATION. August 18, 2017 – B-cell precursor acute lymphoblastic leukemia is a aggressive and rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.. Warning Liver problems have happened with Besponsa (inotuzumab ozogamicin). Sometimes, this has been life-threatening or deadly. The chance of liver problems is higher in people who had a stem cell transplant after treatment with Besponsa (inotuzumab ozogamicin)..
 
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню